Meeting
2017 ASCO Annual Meeting
First-in-human phase 1 study of ETC-159 an oral PORCN inhbitor in patients with advanced solid tumours.
Authors
Matthew Ng
Division of Medical Oncology, National Cancer Centre, Singapore, Singapore
Matthew Ng , David SP Tan , Vivek Subbiah , Colin D. Weekes , Vincenzo Teneggi , Veronica Diermayr , Kantharaj Ethirajulu , Pauline Yeo , Deborah Chen , Stephanie Blanchard , Ranjani Nellore , Bong Hwa Gan , Maryam Yasin , Lay Hoon Lee , May Ann Lee , Jeffrey Hill , Babita Madan , David Virshup , Alex Matter
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02521844
Citation
J Clin Oncol 35, 2017 (suppl; abstr 2584)
DOI
10.1200/JCO.2017.35.15_suppl.2584
Abstract #
2584
Poster Bd #
76
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
NCI 9938: Phase I clinical trial of ATR inhibitor berzosertib (M6620, VX-970) in combination with irinotecan in patients with advanced solid tumors.
First Author: Liza C Villaruz
Poster
2020 ASCO Virtual Scientific Program
Phase I study of regorafenib and sildenafil in advanced solid tumors.
First Author: Andrew Stewart Poklepovic
Poster
2013 ASCO Annual Meeting
A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors.
First Author: Joaquin Mateo
Poster
2023 ASCO Annual Meeting
Lefitolimod (TLR agonist) and ipilimumab in patients with advanced solid tumors: A phase I trial.
First Author: Mirella Nardo